24 June 2020 00:00 until 30 June 2020 07:10

PVRI DDS2020 Digital

digital dds20.jpg

PVRI Drug Discovery & Development Symposium on Pulmonary Hypertension 2020 Digital

In light of the global health and safety recommendations, we will deliver our Symposium in a digital format, in lieu of an in-person event, between 24-29 June 2020. Presentations will be released daily from 24-28 June 2020, leading up to a live session held on 29 June 2020. Opportunities will become available for discussion, Q&A and feedback during this live session. Registration is free and open to all.

29 June 2020 // DDS2020 Live


On Monday 29 June 2020, 15:00-17:00 BST, three keynotes lectures (20 minutes talk followed by 20 minutes Q&A), moderated by Professor Paul Hassoun, Johns Hopkins University School of Medicine, USA, Professor Allan Lawrie, University of Sheffield, UK, and Dr Anna Hemnes, Vanderbilt University Medical Center, USA will be presented live by:

  • Professor Ardeschir Ghofrani, Justus-Liebig-University Giessen, Germany
    Clinical development of inhaled GB002 for the treatment of pulmonary arterial hypertension
    Sponsor: Gossamer Bio
  • Dr David Badesch, University of Colorado, USA
    A study of sotatercept for the treatment of pulmonary arterial hypertension (PULSAR, NCT03496207)
    Sponsor: Acceleron
  • Dr Kathryn Hall, Brigham and Women's Hospital, Harvard Medical School, USA
    Pharmacogenomics and placebo response in a randomised clinical trial

Live access to meeting

The webinar can be accessed by using this link: https://attend.glisser.com/DDSDigital

24-28 June 2020 // Featured presentation releases

We are delighted to introduce a recorded series of featured talks, which will be available as follows:

Wednesday 24 June 2020

  • Eric Austin, Vanderblit University, USA
    Tamoxifen therapy to treat pulmonary arterial hypertension (T3PAH) (NCT03528902)
    Sponsor: Vanderbilt University Medical Center 
  • Luke Howard, Imperial College London, UK
    IV iron replacement for iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) patients (NCT01447628)
    Sponsor: Imperial College London

Thursday 25 June 2020

  • Khodr Tello, Justus-Liebig-University Giessen, Germany
    Right heart III Study: Right ventricular haemodynamic evaluation and response to treatment (NCT03362047)
    Sponsor: Justus-Liebig-University Giessen
  • Ioana Preston, Tufts Medical Center, USA
    Actigraphy as a new endpoint in PAH trials

Friday 26 June 2020

  • Hiromi Matsubara, National Hospital Organization Okayama Medical Center, Japan
    BPA: Where does it come from, where are we and where are we going? 
  • Erika Rosenzweig, Columbia University Medical Center, USA
    A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults
    Sponsor: Columbia University, USA 

Saturday 27 June 2020

  • Shao-Liang Chen, Nanjing First Hospital, Nanjing Medical University, China
    PADN-5: Pulmonary arterial denervation in patients with pulmonary hypertension associated with left heart failure (NCT02220335)
    Sponsor: Nanjing Healthy Bureau & National Science Foundation of China

  • Ronald Oudiz, Harbor-UCLA Faculty Practice Plan, USA
    ABI-009, an mToR Inhibitor, for patients with severe pulmonary arterial hypertension (NCT02587325)
    Sponsor: Aadi, LLC

Sunday 28 June 2020

  • John Scandurra, Aria CV, & Irene Lang, Medical University of Vienna, Autria
    Implantable devices to improve pulmonary circulation compliance
    Sponsor: Aria CV

  • Kelly Chin, UT Southwestern, USA
    Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: Results of the randomised controlled TRITON study (NCT02558231).
    Sponsor: Actelion

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI